Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

CT scans more effective than traditional lung cancer detection methods

A new study led by researchers at Mount Sinai School of Medicine indicates that CT scans are more effective than traditional lung cancer detection methods at identifying aggressive lung cancers in their most treatable stages.

31 Mar 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas ("CPRIT").

31 Mar 2012

Oncothyreon proposes underwritten public offering of common stock

Oncothyreon Inc. today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.

29 Mar 2012

Clovis commences CO-1686 Phase I/II study in NSCLC

Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.

29 Mar 2012

Social rejection, internalized shame may contribute to depression in lung cancer patients

Studying the role of social stigma in depression for lung cancer patients, researchers at Moffitt Cancer Center in Tampa, Fla., have found that depression can be heightened by a lung cancer patient's sense of social rejection, internalized shame and social isolation. These factors may contribute to depression at rates higher than experienced by patients with other kinds of cancer.

26 Mar 2012

East Asian BIM gene variant contributes to drug resistance in cancer

A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.

19 Mar 2012

BRG1 gene loss implies lack of response of cells to retinoic acid and steroids

Retinoic acid (vitamin A) and steroids are hormones found in our body that protect against oxidative stress, reduce inflammation and are involved in cellular differentiation processes. One of the characteristics of tumours is that their cells have lost the ability to differentiate; therefore these hormones have useful properties to prevent cancer. Currently, retinoic acid and steroids are being used to treat some types of leukaemia.

16 Mar 2012

CYFRA reliable marker for response to chemotherapy for NSCLC

Researchers found that CYFRA and change in levels of CYFRA were found to be reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen.

16 Mar 2012

Agennix, DSM sign new contract to manufacture talactoferrin for NSCLC

DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., and Agennix AG have signed a new contract under which DSM will continue to manufacture talactoferrin for Agennix at commercial levels.

13 Mar 2012

Biodesix, Kadmon enter Phase 3 non-small cell lung cancer study collaboration

Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix' VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.

27 Feb 2012

GTx fourth quarter net loss increases to $10.7 million

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2011.

21 Feb 2012

Lung cancer patients with severe COPD can benefit from SBRT

Stereotactic body radiotherapy (SBRT) provides better overall survival rates than surgery for lung cancer patients with severe chronic obstructive pulmonary disease (COPD), a disease commonly associated with lung cancer, according to a study in the upcoming March issue of the International Journal of Radiation, Oncology, Biology, Physics, the official scientific journal of the American Society for Radiation Oncology.

17 Feb 2012

IKK2 enzyme plays a key role in proliferation of lung cancer cells

Drugs targeting an enzyme involved in inflammation might offer a new avenue for treating certain lung cancers, according to a new study by scientists at the Salk Institute for Biological Studies.

17 Feb 2012

Gene sequencing could identify genetic variants of lung cancer and colorectal cancer

Foundation Medicine Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute have come up with the results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.

14 Feb 2012

'Targeted' drugs may be effective against lung and colorectal tumors driven by novel gene abnormalities

Novel gene abnormalities discovered in a subpopulation of lung and colorectal tumors could potentially identify patients with a good chance of responding to highly specific "targeted" drugs already in use for treating other cancers, scientists report.

14 Feb 2012

Discovery of novel rearrangements and fusions supports role for NGS in treatment of cancer

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute today announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.

13 Feb 2012

PORT may not prolong life in older people with NSCLC

Researchers from Mount Sinai School of Medicine have found that post-operative radiation therapy (PORT), a controversial yet frequently administered treatment for lung cancer, may not prolong life in older people with locally advanced disease.

13 Feb 2012

IKBKE protein plays two roles in tobacco-related NSCLC

Researchers at Moffitt Cancer Center in Tampa, Fla., have discovered that the immune response regulator IKBKE (serine/threonine kinase) plays two roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens induce IKBKE and, in turn, IKBKE induces chemotherapy resistance.

10 Feb 2012

Molecular subtypes of lung cancer manifest as different diseases

Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.

3 Feb 2012